Data Year:

For its 2025 fiscal year, KINIKSA PHRMCTICALS INTL PLC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Sanj K. Patel
Chief Executive Officer and Chairman of the Board
Total Compensation $10,782,661 View details Pay Rank By Title In Biotechnology industry #96 View more
John F. Paolini M.D., Ph.D.
Executive Vice President and Chief Medical Officer
Total Compensation $3,570,655 View details Pay Rank By Title In Biotechnology industry #74 View more
Eben Tessari
Executive Vice President and Chief Operating Officer
Total Compensation $3,566,231 View details Pay Rank By Title In Biotechnology industry #48 View more
Ross Moat
Executive Vice President and Chief Commercial Officer
Total Compensation $3,638,001 View details Pay Rank By Title In Biotechnology industry #71 View more
Mark Ragosa
Senior Vice President and Chief Financial Officer
Total Compensation $3,283,055 View details Pay Rank By Title In Biotechnology industry #124 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at KINIKSA PHRMCTICALS INTL PLC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. KINIKSA PHRMCTICALS INTL PLC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. KINIKSA PHRMCTICALS INTL PLC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Sanj K. Patel
Chief Executive Officer and Chairman of the Board
Total Cash $2,227,194 Equity $8,541,467 Other $14,000 $10,782,661
John F. Paolini M.D., Ph.D.
Executive Vice President and Chief Medical Officer
Total Cash $1,116,027 Equity $2,440,628 Other $14,000 $3,570,655
Eben Tessari
Executive Vice President and Chief Operating Officer
Total Cash $1,119,738 Equity $2,440,628 Other $5,865 $3,566,231
Ross Moat
Executive Vice President and Chief Commercial Officer
Total Cash $1,119,595 Equity $2,440,628 Other $77,778 $3,638,001
Mark Ragosa
Senior Vice President and Chief Financial Officer
Total Cash $1,069,500 Equity $2,199,555 Other $14,000 $3,283,055
For its 2025 fiscal year, KINIKSA PHRMCTICALS INTL PLC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Sanj K. Patel CEO Pay $10,782,661 Median Employee Pay $310,707 CEO Pay Ratio 35:1
For its 2024 fiscal year, KINIKSA PHRMCTICALS INTL PLC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Barry D. Quart, Pharm.D Total Cash $350,768
Felix J. Baker, Ph.D. Total Cash $378,943
G. Bradley Cole Total Cash $336,593
Kimberly J. Popovits Total Cash $337,243
M. Cantey Boyd Total Cash $577,252
Richard S. Levy, M.D. Total Cash $430,974
Stephen R. Biggar, M.D., Ph.D. Total Cash $343,193
Thomas R. Malley Total Cash $353,168
Tracey L. McCain Total Cash $336,593
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.